On May 22, 2024 the opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients (APIs), small molecules, of the Porton company took place in Mengeš. This marks another milestone of Porton's globalization journey after the acquisition of J-STAR Research Inc., a US based CRO, in 2017.

Porton je kot prvo tuje podjetje pripeljal v farmacevtsko industrijo koncept pogodbenih raziskav in razvoja ter proizvodnje (angl. CDMO=Contract Development and Manufacturing Organization) na področju farmacevtskih učinkovin, malih molekul. Ob tem Porton odpira nove priložnosti za rast, razvoj in inovacije, ter bo lahko zadovoljil vse večje zahteve svojih kupcev, mednarodnih farmacevtskih družb, po varnosti dobavne verige in inovativnih in zanesljivih storitvah.

The Opening ceremony was hold in the presence of Mr. Jernej Salecl, Director of General Industry, Entrepreneurship and Internationalisation Directorate at Ministry of the economy, tourism and sport, Slovenia.

"The economies of both countries are very much connected and Porton`s investment will significantly and holistically contribute to the further development of one of the most important segments of Slovenian economy - pharmaceutical industry."

Mag. Alenka Suhadolnik, Slovenia Ambasador in People's Republic of China

The initial investment of Porton totaled 50 milion Euros. Our brand renewed facilities include research and development laboratories and a Kilo Lab, featuring state-of-the-art process and analytical equipment. Porton is the first foreign company, who brought to Slovenia the real CDMO business in the field of API’s, small molecules, opening new opportunities for growth, development and innovations.

In addition to openness and reliability, dedication to innovation is the main principle of the company, which upon its arrival in Mengeš also responded to the needs of the local community and at the opening ceremony handed over a donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten.

Till now, Porton PharmaTech d.o.o., the Slovenian subsidiary of Porton Pharma Solutions Ltd., hired over 30 new employees and plans further growth. Porton has also started construction works of the pilot plant, from which in the future Porton will be able to supply its customers, well-known international pharmaceutical companies with the first batches of API's.

"Globalization is Porton's top priority strategy. For Porton, globalization means establishing R&D and manufacturing footprint in US and Europe, so as to meet our global client's increased needs on supply chain security, high quality and innovative and reliable services."

Mr. Oliver Ju, Chairman and CEO of Porton Pharma Solutions Ltd.

About Porton Pharma Solutions Ltd.

Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, TIDES, Biologics, ADCs from pre-clinical to commercial. As of December 31, 2023, we have a proven record for the delivery of more than 3000 projects and established cooperation with more than 1000 global clients.

About Porton PharmaTech, d o.o.

Porton PharmaTech d.o.o. is the European subsidiary of Porton Pharma Solutions Ltd. It is the first CDMO type of company in the pharmaceutical industry in Slovenia, dedicated to provide comprehensive services to Customers, encompassing synthesis route development, process familiarization, analytical methods development and validation and process scale-up.At Porton PharmaTech, d.o.o, Customers are fully supported by an integrated project team committed to deliver services and products within expected timelines and quality.

Disclaimer

This press release contains forward-looking statements and is not a guarantee of future results. They are given on the basis of the management's current views and assumptions regarding future events and business performance. They are subject to risks and uncertainties that include, but are not limited to, future global economic conditions, exchange rates, legal provisions, market conditions, competitor activities and other factors beyond Porton's control. If one or more such risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results could differ materially from those forecast or expected. Any forward-looking statement speaks only as of the date of the particular statement, and Porton undertakes no obligation to publicly update or correct any forward-looking statement except as required by law.